The general objective of our research group is to study the pathophysiological causes and mechanisms of autoimmune systemic inflammatory diseases (rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, etc.), the translational implications of this knowledge in the development and clinical use of novel therapies and biomarkers, and the identification or development of potential therapeutic targets.
The research performed by this group is characterized by a marked translational nature, in such a way that its basic or experimental studies are focused on progressing in the resolution of clinical problems such as the persistence of chronic inflammatory diseases, the absence of curative therapies and, in the case of specific disease forms, such as fibrosis, on the absence of therapies based on its pathogenic mechanisms. The difficult aim of developing personalized medicine in this area is also part of our experimental approach.
We are also significantly dedicated to clinical research and the development of clinical trials in collaboration with the Rheumatology Service of the Hospital 12 de Octubre, and with national cooperative structures such as the Research Network in Inflammation and Rheumatic Diseases (REIR, Red de Investigación en Inflamación y Enfermedades Reumáticas: https://red-rier.org), Spanish national research group LES RELESSER (https://relesser.ser.es), and the European Scleroderma Trials and Research Group (EUSTAR: eustar.org).
The current objectives of this group are the following:
